{"entity":{"id":"lymphoma-roadmap","kind":"roadmap","name":"Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting","aka":["Lymphoma history","Lymphoma evidence roadmap","Hodgkin and non-Hodgkin lymphoma roadmap","How lymphoma treatment was worked out"],"tldr":"Lymphoma was the first cancer shown to be caused by a virus, the first common cancer sorted into subtypes by reading which genes were switched on, and the first in which a patient's own immune cells were reprogrammed to cure them. This roadmap follows the evidence from 1958 to the trials reading out in 2032.","summary":"Lymphoma has been first at more things than any other cancer, and the reason is that you can get hold of it. A lymph node is easy to biopsy, the cells grow in culture, the disease circulates in blood, and it responds to treatment fast enough that a trial reads out in years rather than decades.\n\nThat is why the first human tumour virus was found in it. Denis Burkitt described a jaw tumour in Ugandan children in 1958 and mapped where it occurred; Epstein, Achong and Barr saw virus particles in cells cultured from one of his biopsies in 1964. Twenty years later the first human retrovirus, now called human T-lymphotropic virus type 1, was isolated from the lymphocytes of a patient with a T-cell lymphoma by Poiesz and Gallo, and tied to adult T-cell leukaemia across a Japanese population by Hinuma.\n\nIt is also why lymphoma was the first common cancer taken apart by gene expression. Alizadeh and Staudt showed in 2000 that diffuse large B-cell lymphoma is at least two diseases; Rosenwald turned that into a survival predictor in 2002; Hans gave pathology laboratories a three-stain version in 2004. The genetic classifications followed in 2018, when Chapuy and Schmitz published five clusters and four subtypes within three weeks of each other, and Wright's LymphGen tool in 2020 made it possible to classify one patient's tumour with a probability attached.\n\nTreatment moved on three tracks. In Hodgkin lymphoma the whole effort since the 1990s has been to take treatment away without losing the cure, because the Dutch cohorts showed that 48.5 per cent of survivors develop a second cancer within 40 years and 50 per cent develop cardiovascular disease. HD10 halved the chemotherapy and cut the radiation dose; HD18 and AHL2011 used the scan after two cycles to shorten or soften the intensive regimen; HD16 and EORTC H10 tried to drop radiotherapy on a clear scan and could not. In aggressive B-cell lymphoma, R-CHOP has survived every challenger except one: obinutuzumab failed in GOYA, dose-adjusted EPOCH-R failed in CALGB 50303, ibrutinib failed overall in PHOENIX, and only polatuzumab vedotin in POLARIX improved on it. In indolent lymphoma the question has been how long to treat rather than how hard, and PRIMA answered it with six extra years before relapse and no change in survival.\n\nThe last decade belongs to the immune treatments. ZUMA-1, JULIET and TRANSCEND NHL 001 made CAR-T a third line in large B-cell lymphoma; ZUMA-7 and TRANSFORM moved it to second line, while BELINDA failed in the same setting with a 52-day manufacturing wait. ELARA and ZUMA-5 brought it to follicular lymphoma. The CD20 bispecific antibodies arrived alongside, off the shelf and without apheresis, and inMIND, ELM-2 and ROSEWOOD show the relapsed indolent setting is now crowded with options.\n\nWhat has not been solved: the genetic subtypes have not yet changed a single first-line treatment, the T-cell lymphomas have almost no randomised evidence at all, no trial has shown that acting on a circulating tumour DNA result improves anything, and the drugs that cure this disease are unavailable to most of the people who get it.","asOf":"2026-10-01","links":[{"label":"NCI PDQ: adult non-Hodgkin lymphoma treatment (health professional)","url":"https://www.cancer.gov/types/lymphoma/hp/adult-nhl-treatment-pdq"},{"label":"NCI PDQ: adult Hodgkin lymphoma treatment (health professional)","url":"https://www.cancer.gov/types/lymphoma/hp/adult-hodgkin-treatment-pdq"},{"label":"ESMO clinical practice guidelines: haematological malignancies","url":"https://www.esmo.org/guidelines/esmo-clinical-practice-guidelines-haematological-malignancies"},{"label":"British Society for Haematology guidelines","url":"https://b-s-h.org.uk/guidelines/"},{"label":"ClinicalTrials.gov NCT04685616","url":"https://clinicaltrials.gov/study/NCT04685616"},{"label":"ClinicalTrials.gov NCT06337318","url":"https://clinicaltrials.gov/study/NCT06337318"}],"tags":[],"related":["immunotherapy-roadmap","chemotherapy-roadmap","radiation-roadmap","idea-chemo-free-hodgkin","idea-cd30-car-t-hodgkin","idea-prev-ebv-vaccine","lymphoma-ev-genetic-subtype-directed-first-line","lymphoma-ev-ctdna-instead-of-the-interim-scan","lymphoma-ev-radiotherapy-free-early-hodgkin","lymphoma-ev-fixed-duration-chemotherapy-free-first-line","lymphoma-ev-randomised-evidence-for-the-t-cell-lymphomas","lymphoma-ev-manufacturing-time-as-a-trial-endpoint","lymphoma-ev-the-drugs-that-cure-and-the-places-without-them","lymphoma-ev-late-effects-of-the-treatments-given-now"],"cancers":["non-hodgkin-lymphoma","dlbcl","follicular-lymphoma","mantle-cell-lymphoma","marginal-zone-lymphoma","malt-lymphoma","primary-cns-lymphoma","primary-mediastinal-b-cell-lymphoma","burkitt-lymphoma","peripheral-t-cell-lymphoma","cutaneous-t-cell-lymphoma","hodgkin-lymphoma","early-stage-classical-hodgkin-lymphoma","advanced-stage-classical-hodgkin-lymphoma","relapsed-refractory-hodgkin-lymphoma","waldenstrom"],"sections":["chemotherapy","immunotherapy","cell-therapy","radiation","targeted-therapy","diagnostics","adcs","prevention"],"technologies":["car-t","bispecific-antibody","t-cell-engager","adc","monoclonal-antibody","checkpoint-inhibitor","pet-ct","radiotherapy","liquid-biopsy","wes-wgs","ngs","cytotoxic-chemotherapy"],"targets":["cd20","cd19","cd30","cd79b","cd3","bcl2","bcl6","myc","myd88","ezh2","btk","notch1","notch2","tp53","ccnd1","pd1"],"drugs":["rituximab","obinutuzumab","polatuzumab-vedotin","brentuximab-vedotin","tafasitamab","lenalidomide","ibrutinib","acalabrutinib","zanubrutinib","bendamustine","axicabtagene-ciloleucel","tisagenlecleucel","lisocabtagene-maraleucel","glofitamab","epcoritamab","mosunetuzumab","odronextamab","nivolumab","pembrolizumab","asparaginase"],"companies":["roche-genentech","novartis","gilead","bms","abbvie","genmab","incyte","regeneron","astrazeneca","pfizer","johnson-johnson"],"institutions":["nci","dana-farber","mskcc","cruk","nice","esmo"],"pathways":["bcr-signalling","jak-stat","apoptosis-bcl2"],"terms":["cell-of-origin","lugano-classification","deauville-score","ipi-score","flipi","ctdna","mrd","crs","icans","r-chop","abvd-beacopp","double-hit-lymphoma","autologous-transplant","maintenance-therapy","lymphoma-tx-pod24","lymphoma-tx-car-t-pathway","lymphoma-tx-regimen-alphabet"],"trials":["polarix","echelon-1","echelon-2","hd21","rathl","zuma-1","zuma-5","zuma-7","transform","belinda","epcore-nhl-1","triangle","gallium","relevance","alcanza","ielsg32","ielsg43","starglo","shine","enrich","lyma","flyer","calgb-50303","goya","remarc","polargo","juliet","transcend-nhl-001","prima-follicular","ielsg-19","trog-99-03","elara","rosewood","hd10","hd16","hd18","ahl2011","eortc-h10","jcog9801","smile-enktl","radar-hodgkin","polar-bear","arched","prima-cns","fortplus","mosun-lbt-fl","mosun-len-mzl"],"people":["louis-staudt","ash-alizadeh","gilles-salles","laurie-sehn","martin-dreyling","michael-wang","peter-borchmann","andreas-engert","catherine-thieblemont","franck-morschhauser","andres-ferreri","caron-jacobson","stephen-schuster","jason-westin","michael-dickinson","john-leonard"],"bottlenecks":["b-tumor-heterogeneity","b-biomarker-validation","b-manufacturing-cell-therapy","b-survivorship","b-toxicity-qol","b-aging-comorbidity","b-rare-cancers","b-global-access","b-trial-design","b-negative-results","b-dormancy-mrd","b-drug-pricing"],"keyPapers":["paper-alizadeh-nature","paper-rosenwald-molecular-profiling-dlbcl-nejm-2002","paper-hans-immunohistochemistry-cell-of-origin-dlbcl-blood-2004","paper-chapuy-molecular-subtypes-dlbcl-nat-med-2018","paper-schmitz-genetics-pathogenesis-dlbcl-nejm-2018","paper-wright-lymphgen-genetic-subtypes-dlbcl-cancer-cell-2020","paper-cheson-j-clin-oncol","paper-casulo-pod24-follicular-lymphoma-jco-2015","paper-scherer-ctdna-lymphoma-subtypes-genome-evolution-sci-transl-med-2016","paper-kurtz-j-clin-oncol","paper-burkitt-sarcoma-involving-jaws-african-children-br-j-surg-1958","paper-epstein-virus-particles-burkitt-lymphoblasts-lancet-1964","paper-poiesz-htlv-retrovirus-cutaneous-t-cell-lymphoma-pnas-1980","paper-hinuma-adult-t-cell-leukaemia-antigen-pnas-1981","paper-schaapveld-second-cancer-risk-40-years-hodgkin-nejm-2015","paper-van-nimwegen-cardiovascular-disease-after-hodgkin-jama-intern-med-2015","paper-polarix-polatuzumab-rchp-nejm-2022","paper-zuma-7-axi-cel-second-line-nejm-2022","paper-belinda-tisagenlecleucel-second-line-nejm-2022","paper-ghsg-hd21-brecadd-vs-ebeacopp-advanced-hodgkin-lancet-2024","paper-prima-final-rituximab-maintenance-follicular-jco-2019","paper-enrich-ibrutinib-rituximab-mantle-cell-lancet-2025","paper-inmind-tafasitamab-lenalidomide-rituximab-follicular-lancet-2026"],"journals":[],"dependsOn":[],"notes":[],"steps":[{"era":"1958-1981","title":"Two viruses, found because lymphoma is the cancer you can get hold of","description":"Denis Burkitt described a tumour involving the jaws in African children in 1958 and mapped where it occurred; the geography pointed at an infectious cause. In 1964 Epstein, Achong and Barr saw virus particles in lymphoblasts cultured from one of his biopsies, the first virus ever found in a human tumour, and the start of the field that now includes human papillomavirus, hepatitis B and C, Helicobacter pylori and human herpesvirus 8. Neither paper has an abstract indexed on Europe PMC, so no figure from them is quoted here.\n\nThe second virus came from the other side of the lymphoid system. Poiesz, Gallo and colleagues isolated type C retrovirus particles from the lymphocytes of a patient with a T-cell lymphoma in 1980, the first human retrovirus, characterising a reverse transcriptase that preferred magnesium to manganese and six particle proteins unlike those of any known primate retrovirus. The year after, Hinuma's group in Japan found antibodies to a related antigen in all 44 patients with adult T-cell leukaemia they tested, in 26 per cent of healthy adults from endemic areas and in almost none from elsewhere. Human T-lymphotropic virus type 1 is now screened for in blood donations.","refs":["paper-burkitt-sarcoma-involving-jaws-african-children-br-j-surg-1958","paper-epstein-virus-particles-burkitt-lymphoblasts-lancet-1964","paper-poiesz-htlv-retrovirus-cutaneous-t-cell-lymphoma-pnas-1980","paper-hinuma-adult-t-cell-leukaemia-antigen-pnas-1981","idea-prev-ebv-vaccine"],"status":"historic"},{"era":"1998-2010","title":"How little is enough: the Hodgkin de-escalation programme begins","description":"Hodgkin lymphoma was curable before anyone knew what it was made of, and by the 1990s the question had become how much treatment could be removed. HD10 answered it for early favourable disease, randomising 1,370 patients in a two by two design and finding no difference between four and two cycles of ABVD (five-year freedom from treatment failure 93.0 against 91.1 per cent, p = 0.39) or between 30 Gy and 20 Gy of involved-field radiotherapy (p = 1.00). Two cycles with 20 Gy became the standard, and the four-cycle, 30 Gy group had the most toxicity.\n\nThe reason the question mattered arrived in full later. The Dutch cohorts measured what cure costs: 48.5 per cent of survivors developed a second cancer within 40 years, with risk still raised at 35 years, and 50 per cent developed cardiovascular disease, with coronary heart disease and heart failure still four to six times the population rate after 35 years. The second-cancer risk did not fall for patients treated between 1989 and 2000 compared with those treated in the 1960s and 1970s, despite the less toxic protocols introduced in between.","refs":["paper-ghsg-hd10-reduced-intensity-early-hodgkin-nejm-2010","paper-schaapveld-second-cancer-risk-40-years-hodgkin-nejm-2015","paper-van-nimwegen-cardiovascular-disease-after-hodgkin-jama-intern-med-2015","paper-travis-breast-cancer-after-hodgkin-radiotherapy-jama-2003","hd10","lymphoma-ev-late-effects-of-the-treatments-given-now"],"status":"historic"},{"era":"2000-2020","title":"Reading the genes, and the twenty years it took to make that useful","description":"Alizadeh and Staudt showed in 2000 that diffuse large B-cell lymphoma contains at least two diseases that look identical under the microscope. Rosenwald profiled 240 biopsies in 2002, found germinal-centre, activated and type 3 subgroups, and built a 17-gene survival predictor independent of the International Prognostic Index; the stromal and immune signatures in that paper anticipated the tumour microenvironment era. Hans put the classification within reach of ordinary pathology in 2004, using CD10, BCL6 and MUM1 to split 152 cases into germinal-centre and non-germinal-centre groups with five-year survival of 76 against 34 per cent.\n\nThen the field stalled. The classification predicted outcome but did not direct treatment, and the trials that selected patients by it, PHOENIX among them, failed. The genetic classifications of 2018 were the answer to why: Chapuy's five clusters from 304 tumours and Schmitz's four subtypes from 574 both cut the disease finer than the stain could, and Schmitz's MCD and BN2 subtypes carried a mechanism, chronic active B-cell receptor signalling, with a drug class already in the clinic. Wright's LymphGen tool in 2020 turned cohort clustering into a probability for one patient's tumour, and extended the classification to seven subtypes that share genetics with indolent and extranodal lymphomas.","refs":["paper-alizadeh-nature","paper-rosenwald-molecular-profiling-dlbcl-nejm-2002","paper-hans-immunohistochemistry-cell-of-origin-dlbcl-blood-2004","paper-chapuy-molecular-subtypes-dlbcl-nat-med-2018","paper-schmitz-genetics-pathogenesis-dlbcl-nejm-2018","paper-wright-lymphgen-genetic-subtypes-dlbcl-cancer-cell-2020","paper-phoenix-ibrutinib-r-chop-non-gcb-dlbcl-jco-2019","cell-of-origin","lymphoma-ev-genetic-subtype-directed-first-line"],"status":"historic"},{"era":"2005-2022","title":"Everything that failed to beat R-CHOP, and the one thing that did","description":"R-CHOP has been the first-line standard for aggressive B-cell lymphoma since rituximab was added to CHOP, and almost nothing has improved on it. CALGB 50303 compared dose-adjusted EPOCH-R, which many centres had adopted on single-arm evidence, and found no difference in progression-free or overall survival with substantially more febrile neutropenia, mucositis and neuropathy. GOYA substituted obinutuzumab in 1,418 patients and got a hazard ratio of 0.92 with more grade 3 to 5 and fatal adverse events, despite the same substitution working in follicular lymphoma and chronic lymphocytic leukaemia. REMARC added two years of lenalidomide maintenance and delayed progression without extending life. PHOENIX added ibrutinib and failed overall, helping patients under 60 and harming those over 60 by stopping them finishing the chemotherapy.\n\nWhat worked was subtraction and substitution rather than addition. FLYER showed that four cycles of R-CHOP with two extra rituximab doses was non-inferior to six in young patients with low-risk limited-stage disease, at three-year progression-free survival of 96 per cent and roughly a quarter fewer adverse events. POLARIX replaced vincristine with polatuzumab vedotin and improved progression-free survival, the only first-line improvement in two decades.","refs":["paper-calgb-50303-da-epoch-r-vs-r-chop-jco-2019","paper-goya-obinutuzumab-vs-rituximab-chop-dlbcl-jco-2017","paper-remarc-lenalidomide-maintenance-dlbcl-jco-2017","paper-phoenix-ibrutinib-r-chop-non-gcb-dlbcl-jco-2019","paper-flyer-four-vs-six-cycles-r-chop-lancet-2019","paper-polarix-polatuzumab-rchp-nejm-2022","flyer","calgb-50303","goya","remarc","polarix"],"status":"current"},{"era":"2006-2019","title":"The scan after two cycles, and what it is good for","description":"Four large trials asked the same question from different directions: can a positron emission tomography scan after two cycles of chemotherapy decide what happens next. The answer turned out to be asymmetric.\n\nIntensifying on a positive scan works. EORTC H10 switched scan-positive early-stage patients from ABVD to escalated BEACOPP with involved-node radiotherapy and raised five-year progression-free survival from 77.4 to 90.6 per cent. De-escalating on a negative scan works for chemotherapy. HD18 shortened escalated BEACOPP from six or eight cycles to four in scan-negative advanced disease with five-year progression-free survival of 92.2 against 90.8 per cent and half the severe infections; AHL2011 switched scan-negative patients to ABVD after two cycles of escalated BEACOPP with five-year progression-free survival of 85.7 against 86.2 per cent and grade 3 to 4 anaemia falling from 69 to 28 per cent. RATHL had already shown that bleomycin could be dropped after a negative scan in advanced disease.\n\nDe-escalating on a negative scan does not work for radiotherapy. HD16 omitted 20 Gy after a negative scan and lost 7.3 percentage points of five-year progression-free survival; H10 could not demonstrate non-inferiority in either risk group, and in the favourable group five-year progression-free survival was 99.0 per cent with radiotherapy against 87.1 per cent without.","refs":["paper-eortc-h10-pet-adapted-early-hodgkin-jco-2017","paper-ghsg-hd18-pet-guided-escalated-beacopp-lancet-2017","paper-ahl2011-pet-adapted-treatment-advanced-hodgkin-lancet-oncol-2019","paper-ghsg-hd16-pet-guided-early-favourable-hodgkin-jco-2019","paper-rathl-interim-pet-adapted-abvd-advanced-hodgkin-nejm-2016","hd16","hd18","ahl2011","eortc-h10","rathl","deauville-score","lymphoma-ev-radiotherapy-free-early-hodgkin"],"status":"current"},{"era":"2011-2026","title":"Indolent lymphoma: how long to treat, and the two-year mark that splits the disease","description":"Follicular lymphoma is treated in episodes across decades, so the questions are about duration and sequence rather than intensity. PRIMA randomised 1,018 responders to two years of rituximab maintenance or observation and reported median progression-free survival of 10.5 against 4.1 years at nine years, with ten-year overall survival of about 80 per cent in both arms: the cleanest demonstration in lymphoma that delaying progression and extending life are different things.\n\nCasulo gave the field the marker that matters. Of 588 patients given first-line R-CHOP, 19 per cent progressed within two years, and their five-year overall survival was 50 per cent against 90 per cent, with an index-adjusted hazard ratio of 6.44. That group now triggers a repeat biopsy, because transformation is the commonest cause, and goes to treatment that does not depend on chemotherapy sensitivity.\n\nFor the rest of the disease the options multiplied. GALLIUM and RELEVANCE changed the first line; ELARA and ZUMA-5 brought CAR-T, with complete responses in 69 and 74 per cent; ELM-2 and the other CD20 bispecific antibodies brought off-the-shelf alternatives, with a 73.4 per cent complete response rate for odronextamab; ROSEWOOD paired a Bruton tyrosine kinase inhibitor with a type II antibody; inMIND added a CD19 antibody to lenalidomide and rituximab for a progression-free survival hazard ratio of 0.43. In marginal zone lymphoma, IELSG-19 remains the only randomised first-line systemic trial.","refs":["paper-prima-final-rituximab-maintenance-follicular-jco-2019","paper-casulo-pod24-follicular-lymphoma-jco-2015","paper-elara-tisagenlecleucel-follicular-nat-med-2022","paper-zuma-5-axi-cel-indolent-lymphoma-lancet-oncol-2022","paper-elm-2-odronextamab-follicular-ann-oncol-2024","paper-inmind-tafasitamab-lenalidomide-rituximab-follicular-lancet-2026","paper-ielsg-19-chlorambucil-rituximab-malt-jco-2017","prima-follicular","elara","zuma-5","rosewood","ielsg-19","lymphoma-tx-pod24"],"status":"current"},{"era":"2015-2026","title":"Cells and engagers: the immune treatments that work when chemotherapy does not","description":"ZUMA-1, JULIET and TRANSCEND NHL 001 established CD19 CAR-T in large B-cell lymphoma after two or more lines between 2017 and 2020, with objective responses in 73 per cent and complete responses in 53 per cent in the largest of them, and grade 3 or worse cytokine release syndrome in 2 per cent for lisocabtagene maraleucel against much higher rates for the other products.\n\nThen the three products split in the second line. ZUMA-7 and TRANSFORM both beat salvage chemotherapy with an autologous transplant. BELINDA, testing tisagenlecleucel in the same setting, did not: median event-free survival was 3.0 months in both arms. The explanation most often offered is the 52-day median interval from leukapheresis to infusion, during which 25.9 per cent of the CAR-T group progressed against 13.8 per cent of the standard-care group, compounded by a baseline imbalance that favoured the comparator. It is a cross-trial inference, and the fact that it is the best available explanation for a 322-patient randomised failure says something about how the field measures what it is doing.\n\nThe CD20 bispecific antibodies arrived alongside and solved the logistics rather than the biology: no apheresis, no manufacturing wait, available the week the decision is made. STARGLO, EPCORE NHL-1, POLARGO and ECHELON-3 between them now give transplant-ineligible relapsed diffuse large B-cell lymphoma four options with randomised or pivotal evidence where a decade ago it had none.","refs":["paper-transcend-nhl-001-liso-cel-lancet-2020","paper-juliet-tisagenlecleucel-dlbcl-nejm-2019","paper-zuma-1-axi-cel-nejm-2017","paper-zuma-7-axi-cel-second-line-nejm-2022","paper-transform-liso-cel-lancet-2022","paper-belinda-tisagenlecleucel-second-line-nejm-2022","paper-polargo-polatuzumab-r-gemox-dlbcl-jco-2026","paper-echelon-3-brentuximab-lenalidomide-rituximab-dlbcl-jco-2025","zuma-7","transform","belinda","transcend-nhl-001","juliet","polargo","lymphoma-ev-manufacturing-time-as-a-trial-endpoint"],"status":"current"},{"era":"2017-2026","title":"Mantle cell lymphoma: three ways to use a Bruton tyrosine kinase inhibitor, and none of them extends life","description":"LyMa established three years of rituximab maintenance after autologous transplantation in patients under 66, with four-year event-free survival of 79 against 61 per cent and an overall survival benefit, which is rare for a maintenance strategy in lymphoma.\n\nFor older patients the question became where to put the Bruton tyrosine kinase inhibitor. SHINE added ibrutinib to bendamustine-rituximab and gained 28 months of progression-free survival (80.6 against 52.9 months, hazard ratio 0.75) with no survival difference. ECHO repeated the design with acalabrutinib and gained 17 months (66.4 against 49.6, hazard ratio 0.73), again with no survival difference and grade 3 or greater adverse events in roughly 89 per cent of both arms. ENRICH took the opposite route and removed the chemotherapy: ibrutinib with rituximab beat immunochemotherapy with an adjusted hazard ratio of 0.69, driven almost entirely by the comparison against R-CHOP (0.37) rather than against bendamustine-rituximab (0.91).\n\nTRIANGLE meanwhile asked whether the autologous transplant is still needed in younger patients when ibrutinib is added to induction and maintenance. Taken together, the four trials mean a person over 60 with mantle cell lymphoma now has a chemotherapy-free first-line option, and that nobody has yet shown any of these strategies makes them live longer.","refs":["paper-lyma-rituximab-maintenance-after-transplant-mantle-cell-nejm-2017","paper-shine-ibrutinib-bendamustine-rituximab-mantle-cell-nejm-2022","paper-echo-acalabrutinib-bendamustine-rituximab-mantle-cell-jco-2025","paper-enrich-ibrutinib-rituximab-mantle-cell-lancet-2025","paper-triangle-ibrutinib-mantle-cell-lymphoma-dreyling-lancet-2024","lyma","shine","enrich","triangle","lymphoma-ev-fixed-duration-chemotherapy-free-first-line"],"status":"current"},{"era":"2007-2026","title":"The T-cell lymphomas, where almost nothing has been randomised","description":"Two trials carry most of the randomised evidence for the T-cell lymphomas, and one of them is not randomised. JCOG9801 is the only controlled trial ever run exclusively in adult T-cell leukaemia/lymphoma: 118 patients, a complete response rate of 40 against 25 per cent for an intensive Japanese regimen over biweekly CHOP, three-year overall survival of 24 against 13 per cent that did not reach significance on two-sided testing, and grade 4 thrombocytopenia in 74 against 17 per cent. SMILE is a 38-patient single-arm phase 2 that made extranodal NK/T-cell lymphoma treatable, with an overall response rate of 79 per cent and one-year overall survival of 55 per cent, by building the regimen on asparaginase rather than on an anthracycline.\n\nECHELON-2 is the exception that shows what is possible: brentuximab vedotin with CHP improved survival in CD30-positive peripheral T-cell lymphoma in a global double-blind randomised trial. ALCANZA did the same for cutaneous T-cell lymphoma.\n\nEverything else, including the choice of first-line regimen in peripheral T-cell lymphoma not otherwise specified, rests on single-arm studies and registry series. Several randomised trials are recruiting at last, in peripheral T-cell lymphoma with the T follicular helper phenotype and in NK/T-cell disease.","refs":["paper-jcog9801-vcap-amp-vecp-adult-t-cell-leukaemia-jco-2007","paper-smile-chemotherapy-nk-t-cell-lymphoma-jco-2011","paper-horwitz-lancet","paper-alcanza-brentuximab-vedotin-lancet-2017","jcog9801","smile-enktl","echelon-2","alcanza","lymphoma-ev-randomised-evidence-for-the-t-cell-lymphomas"],"status":"current"},{"era":"2026-2032","title":"What the registry says is coming","description":"The Hodgkin de-escalation question gets its best-designed attempt yet. RADAR (NCT04685616, 1,042 estimated participants; recruiting) randomises ABVD against A2VD, which replaces the bleomycin with brentuximab vedotin, and omits radiotherapy entirely in anyone with a Deauville score of 1 to 3 after two cycles; primary completion is listed for September 2030.\n\nThe oldest patients with diffuse large B-cell lymphoma finally get their own trials. POLAR BEAR (NCT04332822, 300 estimated participants; recruiting) tests polatuzumab vedotin in place of vincristine in R-miniCHOP in people aged 80 or over, or 75 or over and frail by a geriatric assessment, with a primary completion date of 28 December 2025 that has now passed. ARCHED (NCT05820841, 330 estimated participants; recruiting) adds acalabrutinib to R-miniCHOP, with primary completion listed for February 2029.\n\nThe bispecific antibodies move to the front. A National Cancer Institute trial (NCT06337318, 600 estimated participants; recruiting) compares mosunetuzumab with rituximab as first treatment for low tumour burden follicular lymphoma, with primary completion listed for 31 March 2032, and a European trial (NCT06006117, 260 estimated participants; recruiting) runs mosunetuzumab with lenalidomide against the investigator's choice in relapsed marginal zone lymphoma, primary completion September 2027. In primary central nervous system lymphoma, PRIMA-CNS (NCT06830421, 340 estimated participants; recruiting) compares conventional immunochemotherapy with a short induction and an autologous transplant in elderly patients, primary completion 31 August 2029. FORTplus (NCT05045664, 100 estimated participants; recruiting) tests whether an anti-CD20 antibody makes a 4 Gy radiotherapy dose safe in early follicular lymphoma, primary completion 30 September 2027.","refs":["radar-hodgkin","polar-bear","arched","mosun-lbt-fl","mosun-len-mzl","prima-cns","fortplus","lymphoma-ev-radiotherapy-free-early-hodgkin","lymphoma-ev-fixed-duration-chemotherapy-free-first-line"],"status":"emerging"},{"era":"What sets the pace","title":"Four things no trial on this page has fixed","description":"First, the genetics have not reached the clinic. Three classifications and a probabilistic tool exist, and not one first-line treatment decision anywhere is made by genetic subtype outside a trial. The gap between Schmitz in 2018 and a trial that assigns treatment by LymphGen is the clearest unfinished business in the disease.\n\nSecond, nothing acts on a blood test. Circulating tumour DNA predicts outcome at diagnosis, detects residual disease better than imaging, reads cell of origin from plasma and flags transformation before it declares itself, and no randomised trial has yet shown that changing treatment on the strength of it helps anyone.\n\nThird, the T-cell lymphomas have almost no randomised evidence, and the diseases concentrated in east Asia, the Caribbean, west Africa and Latin America have least of all. Adult T-cell leukaemia/lymphoma has had exactly one controlled trial, in 1998.\n\nFourth, access. Rituximab transformed B-cell lymphoma in 1997 and is still unavailable or unaffordable in much of the world; asparaginase, which makes NK/T-cell lymphoma treatable, is intermittently supplied; CAR-T requires an apheresis service, a cryopreservation chain and a centre able to manage cytokine release syndrome. The treatments on this page cure a higher proportion of people with lymphoma than of any other common cancer, in the places that have them.","refs":["paper-wright-lymphgen-genetic-subtypes-dlbcl-cancer-cell-2020","paper-scherer-ctdna-lymphoma-subtypes-genome-evolution-sci-transl-med-2016","paper-jcog9801-vcap-amp-vecp-adult-t-cell-leukaemia-jco-2007","b-global-access","b-rare-cancers","b-biomarker-validation","lymphoma-ev-genetic-subtype-directed-first-line","lymphoma-ev-ctdna-instead-of-the-interim-scan","lymphoma-ev-randomised-evidence-for-the-t-cell-lymphomas","lymphoma-ev-the-drugs-that-cure-and-the-places-without-them"],"status":"current"}],"watch":[{"item":"POLAR BEAR primary completion: polatuzumab vedotin in place of vincristine in R-miniCHOP for patients aged 80 or over, or 75 or over and frail (300 estimated participants; recruiting). The registry date has passed and no report has appeared","expected":"2025-12-28","source":"https://clinicaltrials.gov/study/NCT04332822","refs":["polar-bear","polatuzumab-vedotin"]},{"item":"Mosunetuzumab with lenalidomide against the investigator's choice in relapsed or refractory marginal zone lymphoma, primary completion (260 estimated participants; recruiting)","expected":"2027-09","source":"https://clinicaltrials.gov/study/NCT06006117","refs":["mosun-len-mzl","mosunetuzumab"]},{"item":"FORTplus primary completion: 4 Gy radiotherapy with an anti-CD20 antibody against standard-dose radiotherapy with rituximab in early-stage follicular lymphoma (100 estimated participants; recruiting)","expected":"2027-09-30","source":"https://clinicaltrials.gov/study/NCT05045664","refs":["fortplus","obinutuzumab"]},{"item":"ARCHED primary completion: acalabrutinib added to R-miniCHOP in older adults with untreated diffuse large B-cell lymphoma (330 estimated participants; recruiting)","expected":"2029-02","source":"https://clinicaltrials.gov/study/NCT05820841","refs":["arched","acalabrutinib"]},{"item":"PRIMA-CNS primary completion: conventional immunochemotherapy against short induction with autologous transplant in elderly primary central nervous system lymphoma (340 estimated participants; recruiting)","expected":"2029-08-31","source":"https://clinicaltrials.gov/study/NCT06830421","refs":["prima-cns"]},{"item":"RADAR primary completion: brentuximab vedotin in place of bleomycin, with radiotherapy omitted entirely after a Deauville score of 1 to 3 in early-stage Hodgkin lymphoma (1,042 estimated participants; recruiting)","expected":"2030-09","source":"https://clinicaltrials.gov/study/NCT04685616","refs":["radar-hodgkin","brentuximab-vedotin"]},{"item":"Mosunetuzumab against rituximab as first treatment for low tumour burden follicular lymphoma, primary completion (600 estimated participants; recruiting)","expected":"2032-03-31","source":"https://clinicaltrials.gov/study/NCT06337318","refs":["mosun-lbt-fl","mosunetuzumab"]}]},"route":"/roadmaps/lymphoma-roadmap/","neighbours":{"roadmap":[{"id":"chemotherapy-roadmap","kind":"roadmap","name":"Chemotherapy roadmap: mustard gas → curative combinations → the warhead inside smarter drugs","route":"/roadmaps/chemotherapy-roadmap/"},{"id":"immunotherapy-roadmap","kind":"roadmap","name":"Immunotherapy roadmap: Coley's toxins → checkpoint inhibitors → engineered immunity","route":"/roadmaps/immunotherapy-roadmap/"},{"id":"radiation-roadmap","kind":"roadmap","name":"Radiotherapy roadmap: X-rays → shaped beams → fewer fractions, particles and FLASH","route":"/roadmaps/radiation-roadmap/"}],"idea":[{"id":"lymphoma-ev-radiotherapy-free-early-hodgkin","kind":"idea","name":"A radiotherapy-free cure for early Hodgkin lymphoma that actually holds","route":"/ideas/lymphoma-ev-radiotherapy-free-early-hodgkin/"},{"id":"idea-prev-ebv-vaccine","kind":"idea","name":"An Epstein-Barr virus vaccine to prevent nasopharyngeal cancer and lymphomas","route":"/ideas/idea-prev-ebv-vaccine/"},{"id":"lymphoma-ev-genetic-subtype-directed-first-line","kind":"idea","name":"Assign first-line treatment in diffuse large B-cell lymphoma by genetic subtype, not by a three-antibody stain","route":"/ideas/lymphoma-ev-genetic-subtype-directed-first-line/"},{"id":"idea-cd30-car-t-hodgkin","kind":"idea","name":"CD30 CAR-T for multiply relapsed Hodgkin lymphoma","route":"/ideas/idea-cd30-car-t-hodgkin/"},{"id":"idea-chemo-free-hodgkin","kind":"idea","name":"Chemotherapy-free Hodgkin lymphoma: brentuximab + PD-1 in early stage","route":"/ideas/idea-chemo-free-hodgkin/"},{"id":"lymphoma-ev-fixed-duration-chemotherapy-free-first-line","kind":"idea","name":"Fixed-duration, chemotherapy-free first-line treatment for the indolent lymphomas","route":"/ideas/lymphoma-ev-fixed-duration-chemotherapy-free-first-line/"},{"id":"lymphoma-ev-late-effects-of-the-treatments-given-now","kind":"idea","name":"Measure the late effects of the treatments being given now, not the ones given in 1975","route":"/ideas/lymphoma-ev-late-effects-of-the-treatments-given-now/"},{"id":"lymphoma-ev-randomised-evidence-for-the-t-cell-lymphomas","kind":"idea","name":"Randomised evidence for the T-cell lymphomas, including the ones that are not in Europe or North America","route":"/ideas/lymphoma-ev-randomised-evidence-for-the-t-cell-lymphomas/"},{"id":"lymphoma-ev-manufacturing-time-as-a-trial-endpoint","kind":"idea","name":"Report the time from apheresis to infusion as a trial endpoint, not a logistics footnote","route":"/ideas/lymphoma-ev-manufacturing-time-as-a-trial-endpoint/"},{"id":"lymphoma-ev-the-drugs-that-cure-and-the-places-without-them","kind":"idea","name":"The drugs that cure lymphoma, and the places that do not have them","route":"/ideas/lymphoma-ev-the-drugs-that-cure-and-the-places-without-them/"},{"id":"lymphoma-ev-ctdna-instead-of-the-interim-scan","kind":"idea","name":"Use circulating tumour DNA instead of the interim scan to decide what happens next","route":"/ideas/lymphoma-ev-ctdna-instead-of-the-interim-scan/"}],"cancer":[{"id":"advanced-stage-classical-hodgkin-lymphoma","kind":"cancer","name":"Advanced-stage classical Hodgkin lymphoma (stage III to IV)","route":"/cancers/advanced-stage-classical-hodgkin-lymphoma/"},{"id":"burkitt-lymphoma","kind":"cancer","name":"Burkitt lymphoma","route":"/cancers/burkitt-lymphoma/"},{"id":"cutaneous-t-cell-lymphoma","kind":"cancer","name":"Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome)","route":"/cancers/cutaneous-t-cell-lymphoma/"},{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"early-stage-classical-hodgkin-lymphoma","kind":"cancer","name":"Early-stage classical Hodgkin lymphoma (stage I to II)","route":"/cancers/early-stage-classical-hodgkin-lymphoma/"},{"id":"malt-lymphoma","kind":"cancer","name":"Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)","route":"/cancers/malt-lymphoma/"},{"id":"follicular-lymphoma","kind":"cancer","name":"Follicular lymphoma","route":"/cancers/follicular-lymphoma/"},{"id":"hodgkin-lymphoma","kind":"cancer","name":"Hodgkin lymphoma","route":"/cancers/hodgkin-lymphoma/"},{"id":"mantle-cell-lymphoma","kind":"cancer","name":"Mantle cell lymphoma","route":"/cancers/mantle-cell-lymphoma/"},{"id":"marginal-zone-lymphoma","kind":"cancer","name":"Marginal zone lymphoma","route":"/cancers/marginal-zone-lymphoma/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"},{"id":"peripheral-t-cell-lymphoma","kind":"cancer","name":"Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)","route":"/cancers/peripheral-t-cell-lymphoma/"},{"id":"primary-cns-lymphoma","kind":"cancer","name":"Primary CNS lymphoma","route":"/cancers/primary-cns-lymphoma/"},{"id":"primary-mediastinal-b-cell-lymphoma","kind":"cancer","name":"Primary mediastinal (thymic) large B-cell lymphoma","route":"/cancers/primary-mediastinal-b-cell-lymphoma/"},{"id":"relapsed-refractory-hodgkin-lymphoma","kind":"cancer","name":"Relapsed and refractory classical Hodgkin lymphoma","route":"/cancers/relapsed-refractory-hodgkin-lymphoma/"},{"id":"waldenstrom","kind":"cancer","name":"Waldenström macroglobulinaemia","route":"/cancers/waldenstrom/"}],"section":[{"id":"adcs","kind":"section","name":"Antibody-Drug Conjugates","route":"/fronts/adcs/"},{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/"},{"id":"chemotherapy","kind":"section","name":"Chemotherapy","route":"/fronts/chemotherapy/"},{"id":"diagnostics","kind":"section","name":"Diagnostics & Biomarkers","route":"/fronts/diagnostics/"},{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"},{"id":"prevention","kind":"section","name":"Prevention & Risk","route":"/fronts/prevention/"},{"id":"radiation","kind":"section","name":"Radiation Therapy","route":"/fronts/radiation/"},{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"bispecific-antibody","kind":"technology","name":"Bispecific antibodies","route":"/technologies/bispecific-antibody/"},{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"},{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"},{"id":"pet-ct","kind":"technology","name":"PET/CT","route":"/technologies/pet-ct/"},{"id":"t-cell-engager","kind":"technology","name":"T-cell engagers (bispecific)","route":"/technologies/t-cell-engager/"},{"id":"wes-wgs","kind":"technology","name":"Whole-exome & whole-genome sequencing","route":"/technologies/wes-wgs/"}],"term":[{"id":"abvd-beacopp","kind":"term","name":"ABVD, BEACOPP and BrECADD (Hodgkin lymphoma regimens)","route":"/terms/abvd-beacopp/"},{"id":"autologous-transplant","kind":"term","name":"Autologous stem cell transplant (ASCT)","route":"/terms/autologous-transplant/"},{"id":"cell-of-origin","kind":"term","name":"Cell of origin (GCB vs ABC)","route":"/terms/cell-of-origin/"},{"id":"ctdna","kind":"term","name":"Circulating tumour DNA (ctDNA)","route":"/terms/ctdna/"},{"id":"crs","kind":"term","name":"Cytokine release syndrome (CRS)","route":"/terms/crs/"},{"id":"deauville-score","kind":"term","name":"Deauville five-point scale","route":"/terms/deauville-score/"},{"id":"double-hit-lymphoma","kind":"term","name":"Double-hit / high-grade B-cell lymphoma","route":"/terms/double-hit-lymphoma/"},{"id":"flipi","kind":"term","name":"FLIPI, FLIPI2 and POD24 (follicular lymphoma risk)","route":"/terms/flipi/"},{"id":"icans","kind":"term","name":"ICANS (neurotoxicity)","route":"/terms/icans/"},{"id":"ipi-score","kind":"term","name":"International Prognostic Index (IPI)","route":"/terms/ipi-score/"},{"id":"lugano-classification","kind":"term","name":"Lugano classification / Ann Arbor staging","route":"/terms/lugano-classification/"},{"id":"maintenance-therapy","kind":"term","name":"Maintenance therapy","route":"/terms/maintenance-therapy/"},{"id":"mrd","kind":"term","name":"Minimal / molecular residual disease (MRD)","route":"/terms/mrd/"},{"id":"ngs","kind":"term","name":"Next-generation sequencing (NGS)","route":"/terms/ngs/"},{"id":"lymphoma-tx-pod24","kind":"term","name":"POD24: progression of follicular lymphoma within two years, and why it changes the plan","route":"/terms/lymphoma-tx-pod24/"},{"id":"r-chop","kind":"term","name":"R-CHOP (lymphoma chemoimmunotherapy)","route":"/terms/r-chop/"},{"id":"radiotherapy","kind":"term","name":"Radiotherapy","route":"/terms/radiotherapy/"},{"id":"lymphoma-tx-car-t-pathway","kind":"term","name":"The CAR-T pathway in lymphoma: referral, apheresis, bridging and the waiting","route":"/terms/lymphoma-tx-car-t-pathway/"},{"id":"lymphoma-tx-regimen-alphabet","kind":"term","name":"The lymphoma regimen alphabet: R-CHOP, pola-R-CHP, DA-EPOCH-R, ABVD, BEACOPP and the rest","route":"/terms/lymphoma-tx-regimen-alphabet/"}],"target":[{"id":"bcl2","kind":"target","name":"BCL-2","route":"/targets/bcl2/"},{"id":"bcl6","kind":"target","name":"BCL6","route":"/targets/bcl6/"},{"id":"btk","kind":"target","name":"BTK (Bruton tyrosine kinase)","route":"/targets/btk/"},{"id":"ccnd1","kind":"target","name":"CCND1","route":"/targets/ccnd1/"},{"id":"cd19","kind":"target","name":"CD19","route":"/targets/cd19/"},{"id":"cd20","kind":"target","name":"CD20","route":"/targets/cd20/"},{"id":"cd3","kind":"target","name":"CD3","route":"/targets/cd3/"},{"id":"cd30","kind":"target","name":"CD30","route":"/targets/cd30/"},{"id":"cd79b","kind":"target","name":"CD79b","route":"/targets/cd79b/"},{"id":"ezh2","kind":"target","name":"EZH2","route":"/targets/ezh2/"},{"id":"myd88","kind":"target","name":"MYD88","route":"/targets/myd88/"},{"id":"notch1","kind":"target","name":"NOTCH1","route":"/targets/notch1/"},{"id":"notch2","kind":"target","name":"NOTCH2","route":"/targets/notch2/"},{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"},{"id":"tp53","kind":"target","name":"TP53","route":"/targets/tp53/"}],"pathway":[{"id":"bcr-signalling","kind":"pathway","name":"B-cell receptor / BTK signalling (to NF-κB)","route":"/pathways/bcr-signalling/"},{"id":"apoptosis-bcl2","kind":"pathway","name":"Intrinsic apoptosis (BCL-2 family)","route":"/pathways/apoptosis-bcl2/"},{"id":"jak-stat","kind":"pathway","name":"JAK-STAT signalling","route":"/pathways/jak-stat/"},{"id":"myc","kind":"pathway","name":"MYC","route":"/pathways/myc/"}],"drug":[{"id":"acalabrutinib","kind":"drug","name":"Acalabrutinib","route":"/drugs/acalabrutinib/"},{"id":"asparaginase","kind":"drug","name":"Asparaginase (pegaspargase, calaspargase pegol, Erwinia asparaginase)","route":"/drugs/asparaginase/"},{"id":"axicabtagene-ciloleucel","kind":"drug","name":"Axicabtagene ciloleucel","route":"/drugs/axicabtagene-ciloleucel/"},{"id":"bendamustine","kind":"drug","name":"Bendamustine","route":"/drugs/bendamustine/"},{"id":"brentuximab-vedotin","kind":"drug","name":"Brentuximab vedotin","route":"/drugs/brentuximab-vedotin/"},{"id":"epcoritamab","kind":"drug","name":"Epcoritamab","route":"/drugs/epcoritamab/"},{"id":"glofitamab","kind":"drug","name":"Glofitamab","route":"/drugs/glofitamab/"},{"id":"ibrutinib","kind":"drug","name":"Ibrutinib","route":"/drugs/ibrutinib/"},{"id":"lenalidomide","kind":"drug","name":"Lenalidomide","route":"/drugs/lenalidomide/"},{"id":"lisocabtagene-maraleucel","kind":"drug","name":"Lisocabtagene maraleucel","route":"/drugs/lisocabtagene-maraleucel/"},{"id":"mosunetuzumab","kind":"drug","name":"Mosunetuzumab","route":"/drugs/mosunetuzumab/"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"},{"id":"obinutuzumab","kind":"drug","name":"Obinutuzumab","route":"/drugs/obinutuzumab/"},{"id":"odronextamab","kind":"drug","name":"Odronextamab","route":"/drugs/odronextamab/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"polatuzumab-vedotin","kind":"drug","name":"Polatuzumab vedotin","route":"/drugs/polatuzumab-vedotin/"},{"id":"rituximab","kind":"drug","name":"Rituximab","route":"/drugs/rituximab/"},{"id":"tafasitamab","kind":"drug","name":"Tafasitamab","route":"/drugs/tafasitamab/"},{"id":"tisagenlecleucel","kind":"drug","name":"Tisagenlecleucel","route":"/drugs/tisagenlecleucel/"},{"id":"zanubrutinib","kind":"drug","name":"Zanubrutinib","route":"/drugs/zanubrutinib/"}],"company":[{"id":"abbvie","kind":"company","name":"AbbVie (incl. ImmunoGen, Capstan)","route":"/companies/abbvie/"},{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"},{"id":"bms","kind":"company","name":"Bristol Myers Squibb","route":"/companies/bms/"},{"id":"genmab","kind":"company","name":"Genmab","route":"/companies/genmab/"},{"id":"gilead","kind":"company","name":"Gilead Sciences (incl. Kite)","route":"/companies/gilead/"},{"id":"incyte","kind":"company","name":"Incyte","route":"/companies/incyte/"},{"id":"johnson-johnson","kind":"company","name":"Johnson & Johnson","route":"/companies/johnson-johnson/"},{"id":"novartis","kind":"company","name":"Novartis","route":"/companies/novartis/"},{"id":"pfizer","kind":"company","name":"Pfizer (incl. Seagen)","route":"/companies/pfizer/"},{"id":"regeneron","kind":"company","name":"Regeneron","route":"/companies/regeneron/"},{"id":"roche-genentech","kind":"company","name":"Roche / Genentech","route":"/companies/roche-genentech/"}],"institution":[{"id":"cruk","kind":"institution","name":"Cancer Research UK","route":"/institutions/cruk/"},{"id":"dana-farber","kind":"institution","name":"Dana-Farber Brigham Cancer Center","route":"/institutions/dana-farber/"},{"id":"esmo","kind":"institution","name":"European Society for Medical Oncology (ESMO)","route":"/institutions/esmo/"},{"id":"mskcc","kind":"institution","name":"Memorial Sloan Kettering Cancer Center","route":"/institutions/mskcc/"},{"id":"nci","kind":"institution","name":"National Cancer Institute (NIH)","route":"/institutions/nci/"},{"id":"nice","kind":"institution","name":"National Institute for Health and Care Excellence","route":"/institutions/nice/"}],"trial":[{"id":"nct04680052","kind":"trial","name":"A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Pa","route":"/trials/nct04680052/"},{"id":"nct02972840","kind":"trial","name":"A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL","route":"/trials/nct02972840/"},{"id":"nct03888105","kind":"trial","name":"A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treat","route":"/trials/nct03888105/"},{"id":"ahl2011","kind":"trial","name":"AHL2011","route":"/trials/ahl2011/"},{"id":"alcanza","kind":"trial","name":"ALCANZA","route":"/trials/alcanza/"},{"id":"calgb-50303","kind":"trial","name":"Alliance/CALGB 50303","route":"/trials/calgb-50303/"},{"id":"arched","kind":"trial","name":"ARCHED","route":"/trials/arched/"},{"id":"belinda","kind":"trial","name":"BELINDA","route":"/trials/belinda/"},{"id":"nct04404283","kind":"trial","name":"Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL","route":"/trials/nct04404283/"},{"id":"echelon-1","kind":"trial","name":"ECHELON-1","route":"/trials/echelon-1/"},{"id":"echelon-2","kind":"trial","name":"ECHELON-2","route":"/trials/echelon-2/"},{"id":"elara","kind":"trial","name":"ELARA","route":"/trials/elara/"},{"id":"enrich","kind":"trial","name":"ENRICH","route":"/trials/enrich/"},{"id":"eortc-h10","kind":"trial","name":"EORTC/LYSA/FIL H10","route":"/trials/eortc-h10/"},{"id":"epcore-nhl-1","kind":"trial","name":"EPCORE NHL-1","route":"/trials/epcore-nhl-1/"},{"id":"flyer","kind":"trial","name":"FLYER","route":"/trials/flyer/"},{"id":"fortplus","kind":"trial","name":"FORTplus","route":"/trials/fortplus/"},{"id":"gallium","kind":"trial","name":"GALLIUM","route":"/trials/gallium/"},{"id":"hd10","kind":"trial","name":"GHSG HD10","route":"/trials/hd10/"},{"id":"hd16","kind":"trial","name":"GHSG HD16","route":"/trials/hd16/"},{"id":"hd18","kind":"trial","name":"GHSG HD18","route":"/trials/hd18/"},{"id":"hd21","kind":"trial","name":"GHSG HD21","route":"/trials/hd21/"},{"id":"goya","kind":"trial","name":"GOYA","route":"/trials/goya/"},{"id":"ielsg-19","kind":"trial","name":"IELSG-19","route":"/trials/ielsg-19/"},{"id":"ielsg32","kind":"trial","name":"IELSG32","route":"/trials/ielsg32/"},{"id":"jcog9801","kind":"trial","name":"JCOG9801","route":"/trials/jcog9801/"},{"id":"juliet","kind":"trial","name":"JULIET","route":"/trials/juliet/"},{"id":"lyma","kind":"trial","name":"LyMa","route":"/trials/lyma/"},{"id":"ielsg43","kind":"trial","name":"MATRix/IELSG43","route":"/trials/ielsg43/"},{"id":"mosun-lbt-fl","kind":"trial","name":"Mosunetuzumab against rituximab in low tumour burden follicular lymphoma","route":"/trials/mosun-lbt-fl/"},{"id":"mosun-len-mzl","kind":"trial","name":"Mosunetuzumab with lenalidomide in relapsed marginal zone lymphoma","route":"/trials/mosun-len-mzl/"},{"id":"phoenix","kind":"trial","name":"PHOENIX DDR/Anti-PD-L1","route":"/trials/phoenix/"},{"id":"polar-bear","kind":"trial","name":"POLAR BEAR","route":"/trials/polar-bear/"},{"id":"polargo","kind":"trial","name":"POLARGO","route":"/trials/polargo/"},{"id":"polarix","kind":"trial","name":"POLARIX","route":"/trials/polarix/"},{"id":"prima-follicular","kind":"trial","name":"PRIMA","route":"/trials/prima-follicular/"},{"id":"prima-cns","kind":"trial","name":"PRIMA-CNS","route":"/trials/prima-cns/"},{"id":"radar-hodgkin","kind":"trial","name":"RADAR","route":"/trials/radar-hodgkin/"},{"id":"rathl","kind":"trial","name":"RATHL","route":"/trials/rathl/"},{"id":"relevance","kind":"trial","name":"RELEVANCE","route":"/trials/relevance/"},{"id":"remarc","kind":"trial","name":"REMARC","route":"/trials/remarc/"},{"id":"rosewood","kind":"trial","name":"ROSEWOOD","route":"/trials/rosewood/"},{"id":"shine","kind":"trial","name":"SHINE","route":"/trials/shine/"},{"id":"smile-enktl","kind":"trial","name":"SMILE","route":"/trials/smile-enktl/"},{"id":"starglo","kind":"trial","name":"STARGLO","route":"/trials/starglo/"},{"id":"transcend-nhl-001","kind":"trial","name":"TRANSCEND NHL 001","route":"/trials/transcend-nhl-001/"},{"id":"transform","kind":"trial","name":"TRANSFORM","route":"/trials/transform/"},{"id":"triangle","kind":"trial","name":"TRIANGLE","route":"/trials/triangle/"},{"id":"trog-99-03","kind":"trial","name":"TROG 99.03","route":"/trials/trog-99-03/"},{"id":"zuma-1","kind":"trial","name":"ZUMA-1","route":"/trials/zuma-1/"},{"id":"zuma-5","kind":"trial","name":"ZUMA-5","route":"/trials/zuma-5/"},{"id":"zuma-7","kind":"trial","name":"ZUMA-7","route":"/trials/zuma-7/"}],"person":[{"id":"andreas-engert","kind":"person","name":"Andreas Engert","route":"/people/andreas-engert/"},{"id":"andres-ferreri","kind":"person","name":"Andrés J. M. Ferreri","route":"/people/andres-ferreri/"},{"id":"ash-alizadeh","kind":"person","name":"Ash A. Alizadeh","route":"/people/ash-alizadeh/"},{"id":"caron-jacobson","kind":"person","name":"Caron A. Jacobson","route":"/people/caron-jacobson/"},{"id":"catherine-thieblemont","kind":"person","name":"Catherine Thieblemont","route":"/people/catherine-thieblemont/"},{"id":"franck-morschhauser","kind":"person","name":"Franck Morschhauser","route":"/people/franck-morschhauser/"},{"id":"gilles-salles","kind":"person","name":"Gilles Salles","route":"/people/gilles-salles/"},{"id":"jason-westin","kind":"person","name":"Jason R. Westin","route":"/people/jason-westin/"},{"id":"john-leonard","kind":"person","name":"John P. Leonard","route":"/people/john-leonard/"},{"id":"laurie-sehn","kind":"person","name":"Laurie H. Sehn","route":"/people/laurie-sehn/"},{"id":"louis-staudt","kind":"person","name":"Louis M. Staudt","route":"/people/louis-staudt/"},{"id":"martin-dreyling","kind":"person","name":"Martin Dreyling","route":"/people/martin-dreyling/"},{"id":"michael-dickinson","kind":"person","name":"Michael Dickinson","route":"/people/michael-dickinson/"},{"id":"michael-wang","kind":"person","name":"Michael L. Wang","route":"/people/michael-wang/"},{"id":"peter-borchmann","kind":"person","name":"Peter Borchmann","route":"/people/peter-borchmann/"},{"id":"stephen-schuster","kind":"person","name":"Stephen J. Schuster","route":"/people/stephen-schuster/"}],"bottleneck":[{"id":"b-biomarker-validation","kind":"bottleneck","name":"Biomarkers are not validated or standardised","route":"/bottlenecks/b-biomarker-validation/"},{"id":"b-dormancy-mrd","kind":"bottleneck","name":"Dormant cells and minimal residual disease","route":"/bottlenecks/b-dormancy-mrd/"},{"id":"b-negative-results","kind":"bottleneck","name":"Failures are hidden","route":"/bottlenecks/b-negative-results/"},{"id":"b-manufacturing-cell-therapy","kind":"bottleneck","name":"Manufacturing cost and time for living and radioactive medicines","route":"/bottlenecks/b-manufacturing-cell-therapy/"},{"id":"b-global-access","kind":"bottleneck","name":"Most of the world has almost no cancer care","route":"/bottlenecks/b-global-access/"},{"id":"b-aging-comorbidity","kind":"bottleneck","name":"Older and multimorbid patients are excluded and undertreated","route":"/bottlenecks/b-aging-comorbidity/"},{"id":"b-drug-pricing","kind":"bottleneck","name":"Prices and value","route":"/bottlenecks/b-drug-pricing/"},{"id":"b-rare-cancers","kind":"bottleneck","name":"Rare and paediatric cancers without markets","route":"/bottlenecks/b-rare-cancers/"},{"id":"b-survivorship","kind":"bottleneck","name":"Survivorship and late effects are neglected","route":"/bottlenecks/b-survivorship/"},{"id":"b-toxicity-qol","kind":"bottleneck","name":"Toxicity and quality of life are undervalued","route":"/bottlenecks/b-toxicity-qol/"},{"id":"b-trial-design","kind":"bottleneck","name":"Trial design, endpoints and cost","route":"/bottlenecks/b-trial-design/"},{"id":"b-tumor-heterogeneity","kind":"bottleneck","name":"Tumour heterogeneity and clonal evolution","route":"/bottlenecks/b-tumor-heterogeneity/"}],"paper":[{"id":"paper-wright-lymphgen-genetic-subtypes-dlbcl-cancer-cell-2020","kind":"paper","name":"A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications","route":"/key-papers/paper-wright-lymphgen-genetic-subtypes-dlbcl-cancer-cell-2020/"},{"id":"paper-burkitt-sarcoma-involving-jaws-african-children-br-j-surg-1958","kind":"paper","name":"A sarcoma involving the jaws in African children","route":"/key-papers/paper-burkitt-sarcoma-involving-jaws-african-children-br-j-surg-1958/"},{"id":"paper-echo-acalabrutinib-bendamustine-rituximab-mantle-cell-jco-2025","kind":"paper","name":"Acalabrutinib plus bendamustine-rituximab in untreated mantle cell lymphoma","route":"/key-papers/paper-echo-acalabrutinib-bendamustine-rituximab-mantle-cell-jco-2025/"},{"id":"paper-hinuma-adult-t-cell-leukaemia-antigen-pnas-1981","kind":"paper","name":"Adult T-cell leukemia: antigen in an ATL cell line and detection of antibodies to the antigen in human sera","route":"/key-papers/paper-hinuma-adult-t-cell-leukaemia-antigen-pnas-1981/"},{"id":"paper-alcanza-brentuximab-vedotin-lancet-2017","kind":"paper","name":"ALCANZA: brentuximab vedotin versus physician's choice in CD30-positive cutaneous T-cell lymphoma","route":"/key-papers/paper-alcanza-brentuximab-vedotin-lancet-2017/"},{"id":"paper-zuma-5-axi-cel-indolent-lymphoma-lancet-oncol-2022","kind":"paper","name":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","route":"/key-papers/paper-zuma-5-axi-cel-indolent-lymphoma-lancet-oncol-2022/"},{"id":"paper-travis-breast-cancer-after-hodgkin-radiotherapy-jama-2003","kind":"paper","name":"Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease","route":"/key-papers/paper-travis-breast-cancer-after-hodgkin-radiotherapy-jama-2003/"},{"id":"paper-echelon-3-brentuximab-lenalidomide-rituximab-dlbcl-jco-2025","kind":"paper","name":"Brentuximab vedotin combination for relapsed diffuse large B-cell lymphoma","route":"/key-papers/paper-echelon-3-brentuximab-lenalidomide-rituximab-dlbcl-jco-2025/"},{"id":"paper-horwitz-lancet","kind":"paper","name":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","route":"/key-papers/paper-horwitz-lancet/"},{"id":"paper-van-nimwegen-cardiovascular-disease-after-hodgkin-jama-intern-med-2015","kind":"paper","name":"Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk","route":"/key-papers/paper-van-nimwegen-cardiovascular-disease-after-hodgkin-jama-intern-med-2015/"},{"id":"paper-kurtz-j-clin-oncol","kind":"paper","name":"Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma","route":"/key-papers/paper-kurtz-j-clin-oncol/"},{"id":"paper-hans-immunohistochemistry-cell-of-origin-dlbcl-blood-2004","kind":"paper","name":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","route":"/key-papers/paper-hans-immunohistochemistry-cell-of-origin-dlbcl-blood-2004/"},{"id":"paper-poiesz-htlv-retrovirus-cutaneous-t-cell-lymphoma-pnas-1980","kind":"paper","name":"Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma","route":"/key-papers/paper-poiesz-htlv-retrovirus-cutaneous-t-cell-lymphoma-pnas-1980/"},{"id":"paper-scherer-ctdna-lymphoma-subtypes-genome-evolution-sci-transl-med-2016","kind":"paper","name":"Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumour DNA","route":"/key-papers/paper-scherer-ctdna-lymphoma-subtypes-genome-evolution-sci-transl-med-2016/"},{"id":"paper-alizadeh-nature","kind":"paper","name":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","route":"/key-papers/paper-alizadeh-nature/"},{"id":"paper-calgb-50303-da-epoch-r-vs-r-chop-jco-2019","kind":"paper","name":"Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the phase III intergroup trial Alliance/CALGB 50303","route":"/key-papers/paper-calgb-50303-da-epoch-r-vs-r-chop-jco-2019/"},{"id":"paper-eortc-h10-pet-adapted-early-hodgkin-jco-2017","kind":"paper","name":"Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC/LYSA/FIL H10 trial","route":"/key-papers/paper-eortc-h10-pet-adapted-early-hodgkin-jco-2017/"},{"id":"paper-casulo-pod24-follicular-lymphoma-jco-2015","kind":"paper","name":"Early relapse of follicular lymphoma after R-CHOP defines patients at high risk for death: an analysis from the National LymphoCare Study","route":"/key-papers/paper-casulo-pod24-follicular-lymphoma-jco-2015/"},{"id":"paper-kurtz-nat-biotechnol","kind":"paper","name":"Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA","route":"/key-papers/paper-kurtz-nat-biotechnol/"},{"id":"paper-ielsg-19-chlorambucil-rituximab-malt-jco-2017","kind":"paper","name":"Final results of the IELSG-19 randomized trial of mucosa-associated lymphoid tissue lymphoma: improved event-free and progression-free survival with rituximab plus chlorambucil versus either chlorambucil or rituximab monotherapy","route":"/key-papers/paper-ielsg-19-chlorambucil-rituximab-malt-jco-2017/"},{"id":"paper-fort-long-term-follow-up-hoskin-lancet-oncol-2021","kind":"paper","name":"FoRT long-term follow-up: 4 Gy versus 24 Gy for follicular and marginal zone lymphoma","route":"/key-papers/paper-fort-long-term-follow-up-hoskin-lancet-oncol-2021/"},{"id":"paper-fort-4gy-vs-24gy-indolent-lymphoma-hoskin-lancet-oncol-2014","kind":"paper","name":"FoRT: 4 Gy versus 24 Gy radiotherapy for indolent lymphoma, a randomised phase 3 non-inferiority trial","route":"/key-papers/paper-fort-4gy-vs-24gy-indolent-lymphoma-hoskin-lancet-oncol-2014/"},{"id":"paper-flyer-four-vs-six-cycles-r-chop-lancet-2019","kind":"paper","name":"Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER)","route":"/key-papers/paper-flyer-four-vs-six-cycles-r-chop-lancet-2019/"},{"id":"paper-schmitz-genetics-pathogenesis-dlbcl-nejm-2018","kind":"paper","name":"Genetics and pathogenesis of diffuse large B-cell lymphoma","route":"/key-papers/paper-schmitz-genetics-pathogenesis-dlbcl-nejm-2018/"},{"id":"paper-ghsg-hd10-reduced-intensity-early-hodgkin-nejm-2010","kind":"paper","name":"GHSG HD10: reduced treatment intensity in early-stage favourable Hodgkin lymphoma","route":"/key-papers/paper-ghsg-hd10-reduced-intensity-early-hodgkin-nejm-2010/"},{"id":"paper-ghsg-hd21-brecadd-vs-ebeacopp-advanced-hodgkin-lancet-2024","kind":"paper","name":"GHSG HD21: PET-guided BrECADD versus escalated BEACOPP in advanced-stage classical Hodgkin lymphoma","route":"/key-papers/paper-ghsg-hd21-brecadd-vs-ebeacopp-advanced-hodgkin-lancet-2024/"},{"id":"paper-enrich-ibrutinib-rituximab-mantle-cell-lancet-2025","kind":"paper","name":"Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH): a randomised, open-label, phase 2/3 superiority trial","route":"/key-papers/paper-enrich-ibrutinib-rituximab-mantle-cell-lancet-2025/"},{"id":"paper-shine-ibrutinib-bendamustine-rituximab-mantle-cell-nejm-2022","kind":"paper","name":"Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma","route":"/key-papers/paper-shine-ibrutinib-bendamustine-rituximab-mantle-cell-nejm-2022/"},{"id":"paper-juliet-tisagenlecleucel-dlbcl-nejm-2019","kind":"paper","name":"JULIET: tisagenlecleucel for adults with relapsed or refractory diffuse large B-cell lymphoma","route":"/key-papers/paper-juliet-tisagenlecleucel-dlbcl-nejm-2019/"},{"id":"paper-remarc-lenalidomide-maintenance-dlbcl-jco-2017","kind":"paper","name":"Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line R-CHOP","route":"/key-papers/paper-remarc-lenalidomide-maintenance-dlbcl-jco-2017/"},{"id":"paper-transcend-nhl-001-liso-cel-lancet-2020","kind":"paper","name":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","route":"/key-papers/paper-transcend-nhl-001-liso-cel-lancet-2020/"},{"id":"paper-chapuy-molecular-subtypes-dlbcl-nat-med-2018","kind":"paper","name":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","route":"/key-papers/paper-chapuy-molecular-subtypes-dlbcl-nat-med-2018/"},{"id":"paper-goya-obinutuzumab-vs-rituximab-chop-dlbcl-jco-2017","kind":"paper","name":"Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma","route":"/key-papers/paper-goya-obinutuzumab-vs-rituximab-chop-dlbcl-jco-2017/"},{"id":"paper-ahl2011-pet-adapted-treatment-advanced-hodgkin-lancet-oncol-2019","kind":"paper","name":"PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study","route":"/key-papers/paper-ahl2011-pet-adapted-treatment-advanced-hodgkin-lancet-oncol-2019/"},{"id":"paper-ghsg-hd18-pet-guided-escalated-beacopp-lancet-2017","kind":"paper","name":"PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group","route":"/key-papers/paper-ghsg-hd18-pet-guided-escalated-beacopp-lancet-2017/"},{"id":"paper-smile-chemotherapy-nk-t-cell-lymphoma-jco-2011","kind":"paper","name":"Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study","route":"/key-papers/paper-smile-chemotherapy-nk-t-cell-lymphoma-jco-2011/"},{"id":"paper-polarix-polatuzumab-rchp-nejm-2022","kind":"paper","name":"POLARIX: swapping vincristine for the antibody-drug conjugate polatuzumab vedotin in first-line treatment of diffuse large B-cell lymphoma","route":"/key-papers/paper-polarix-polatuzumab-rchp-nejm-2022/"},{"id":"paper-polargo-polatuzumab-r-gemox-dlbcl-jco-2026","kind":"paper","name":"Polatuzumab vedotin plus rituximab, gemcitabine, and oxaliplatin in relapsed or refractory diffuse large B-cell lymphoma: results from the phase III, randomized POLARGO trial","route":"/key-papers/paper-polargo-polatuzumab-r-gemox-dlbcl-jco-2026/"},{"id":"paper-ghsg-hd16-pet-guided-early-favourable-hodgkin-jco-2019","kind":"paper","name":"Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: final results of the international, randomized phase III HD16 trial by the German Hodgkin Study Group","route":"/key-papers/paper-ghsg-hd16-pet-guided-early-favourable-hodgkin-jco-2019/"},{"id":"paper-phoenix-ibrutinib-r-chop-non-gcb-dlbcl-jco-2019","kind":"paper","name":"Randomized phase III trial of ibrutinib and R-CHOP in non-germinal centre B-cell diffuse large B-cell lymphoma (PHOENIX)","route":"/key-papers/paper-phoenix-ibrutinib-r-chop-non-gcb-dlbcl-jco-2019/"},{"id":"paper-trog-99-03-radiotherapy-systemic-therapy-early-follicular-jco-2018","kind":"paper","name":"Randomized trial of systemic therapy after involved-field radiotherapy in patients with early-stage follicular lymphoma: TROG 99.03","route":"/key-papers/paper-trog-99-03-radiotherapy-systemic-therapy-early-follicular-jco-2018/"},{"id":"paper-rathl-interim-pet-adapted-abvd-advanced-hodgkin-nejm-2016","kind":"paper","name":"RATHL: adapted treatment guided by interim PET-CT in advanced Hodgkin lymphoma","route":"/key-papers/paper-rathl-interim-pet-adapted-abvd-advanced-hodgkin-nejm-2016/"},{"id":"paper-cheson-j-clin-oncol","kind":"paper","name":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","route":"/key-papers/paper-cheson-j-clin-oncol/"},{"id":"paper-wotherspoon-h-pylori-malt-lancet-1993","kind":"paper","name":"Regression of primary low-grade gastric MALT lymphoma after eradication of Helicobacter pylori","route":"/key-papers/paper-wotherspoon-h-pylori-malt-lancet-1993/"},{"id":"paper-lyma-rituximab-maintenance-after-transplant-mantle-cell-nejm-2017","kind":"paper","name":"Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma","route":"/key-papers/paper-lyma-rituximab-maintenance-after-transplant-mantle-cell-nejm-2017/"},{"id":"paper-prima-rituximab-maintenance-follicular-lancet-2011","kind":"paper","name":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial","route":"/key-papers/paper-prima-rituximab-maintenance-follicular-lancet-2011/"},{"id":"paper-rosewood-zanubrutinib-obinutuzumab-follicular-jco-2023","kind":"paper","name":"ROSEWOOD: a phase II randomized study of zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy in patients with relapsed or refractory follicular lymphoma","route":"/key-papers/paper-rosewood-zanubrutinib-obinutuzumab-follicular-jco-2023/"},{"id":"paper-elm-2-odronextamab-follicular-ann-oncol-2024","kind":"paper","name":"Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma","route":"/key-papers/paper-elm-2-odronextamab-follicular-ann-oncol-2024/"},{"id":"paper-schaapveld-second-cancer-risk-40-years-hodgkin-nejm-2015","kind":"paper","name":"Second cancer risk up to 40 years after treatment for Hodgkin's lymphoma","route":"/key-papers/paper-schaapveld-second-cancer-risk-40-years-hodgkin-nejm-2015/"},{"id":"paper-belinda-tisagenlecleucel-second-line-nejm-2022","kind":"paper","name":"Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma","route":"/key-papers/paper-belinda-tisagenlecleucel-second-line-nejm-2022/"},{"id":"paper-prima-final-rituximab-maintenance-follicular-jco-2019","kind":"paper","name":"Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA study","route":"/key-papers/paper-prima-final-rituximab-maintenance-follicular-jco-2019/"},{"id":"paper-inmind-tafasitamab-lenalidomide-rituximab-follicular-lancet-2026","kind":"paper","name":"Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial","route":"/key-papers/paper-inmind-tafasitamab-lenalidomide-rituximab-follicular-lancet-2026/"},{"id":"paper-rosenwald-molecular-profiling-dlbcl-nejm-2002","kind":"paper","name":"The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma","route":"/key-papers/paper-rosenwald-molecular-profiling-dlbcl-nejm-2002/"},{"id":"paper-elara-tisagenlecleucel-follicular-nat-med-2022","kind":"paper","name":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial","route":"/key-papers/paper-elara-tisagenlecleucel-follicular-nat-med-2022/"},{"id":"paper-transform-liso-cel-lancet-2022","kind":"paper","name":"TRANSFORM: liso-cel CAR-T versus salvage chemotherapy and transplant in early-relapsing large B-cell lymphoma","route":"/key-papers/paper-transform-liso-cel-lancet-2022/"},{"id":"paper-triangle-ibrutinib-mantle-cell-lymphoma-dreyling-lancet-2024","kind":"paper","name":"TRIANGLE: ibrutinib with immunochemotherapy with or without autologous transplant versus immunochemotherapy and transplant in untreated mantle cell lymphoma","route":"/key-papers/paper-triangle-ibrutinib-mantle-cell-lymphoma-dreyling-lancet-2024/"},{"id":"paper-jcog9801-vcap-amp-vecp-adult-t-cell-leukaemia-jco-2007","kind":"paper","name":"VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801","route":"/key-papers/paper-jcog9801-vcap-amp-vecp-adult-t-cell-leukaemia-jco-2007/"},{"id":"paper-epstein-virus-particles-burkitt-lymphoblasts-lancet-1964","kind":"paper","name":"Virus particles in cultured lymphoblasts from Burkitt's lymphoma","route":"/key-papers/paper-epstein-virus-particles-burkitt-lymphoblasts-lancet-1964/"},{"id":"paper-zuma-1-axi-cel-nejm-2017","kind":"paper","name":"ZUMA-1: axicabtagene ciloleucel for refractory large B-cell lymphoma, the first CAR-T approved for lymphoma","route":"/key-papers/paper-zuma-1-axi-cel-nejm-2017/"},{"id":"paper-zuma-7-axi-cel-second-line-nejm-2022","kind":"paper","name":"ZUMA-7: axi-cel CAR-T instead of salvage chemotherapy and transplant for large B-cell lymphoma that relapses early","route":"/key-papers/paper-zuma-7-axi-cel-second-line-nejm-2022/"}]}}